New Cholesterol Guidelines Look for Long Lasting Results Part 3

With a new class of drugs on the horizon questions remain about what PCSK9 inhibitors will mean to the future of cardiac care. Doctors are slowly learning the answers to those questions as possible approval draws closer.

C. Noel Bairey Merz, MD, FACC, FAHA, from the Cedars Sinai Heart Institute discussed what the potential new medications can mean for patient treatment at the American College of Cardiology Scientific Sessions and Expo in San Diego.